济南早泄的西医治疗(济南现在割包茎需要多少钱) (今日更新中)

XICHANG, Sichuan, June 21 (Xinhua) -- China successfully launched a new communication satellite, the Zhongxing-10, from its Xichang Satellite Launch Center in southwest Sichuan Province on early Tuesday.The satellite, carried by a Long March-3B rocket carrier, blasted off from the center at 0:13 a.m., said a statement from the center.According to statistics from the control center, the satellite successfully separated from its carrier rocket and entered Earth's orbit as scheduled, 26 minutes after being launched.The Zhongxing-10 was designed and manufactured by the China Academy of Space Technology under the China Aerospace Science and Technology Corporation.The satellite will provide communication, broadcasting and data transmission services for users in China and the Asia-Pacific region. It will replace the Zhongxing-5B satellite, which was launched in 1998.The launch was the 138th mission for the Long March carrier rocket series.

SYDNEY, July 1 (Xinhua) -- Breastfeeding mothers should limit their use of codeine-containing painkillers to four days as they can cause harm, an Australian doctor warned on Friday.The warning is being discussed at a meeting of anesthetists in Sydney."New mothers should limit their use of codeine-containing painkillers to no more than four days and, if they feel drowsy while taking this medication, cease its use and have their baby examined by a doctor for signs of drowsiness," Sydney's Royal North Shore Hospital anesthetist Dr. Gavin Pattullo said."This is because codeine needs to be metabolized by the liver into morphine to offer pain relief and this liver conversion process is very unpredictable," Pattullo said."Some patients' livers produce large amounts of morphine after taking codeine, causing drowsiness, while others fail to produce any morphine at all."Pattullo said for breastfeeding mothers, a large dose of morphine could make its way into the baby and result in the baby's death by overdose."While new mums shouldn't be unnecessarily alarmed, they need to be aware that codeine-containing painkillers in certain circumstances can cause harm," he said.Breastfeeding mothers are being advised to see a doctor if their baby gets sleepy while taking the painkillers.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Sept. 6 (Xinhuanet) -- The amount of space junks floating in Earth's orbit has reached a critical level, warned scientists.The future space missions may become too dangerous to fly for a risk of colliding with space junks, said a report released recently by the U.S. National Research Council (NRC).The kinds of space junks range from huge, the report said, there are thousands of discarded satellites and rocket boosters and countless tiny pieces of daily gabages from space missions.The debris are traveling in orbit at 17,500mph, at such a speed even a tiny clash can destroy a spacecraft.The NRC recommended that NASA should launch a plan to clean up the floating debris and called on other major space nations' cooperation."The current space environment is growing increasingly hazardous to spacecraft and astronauts," said Kessler, an ex-NASA researcher, "NASA needs to determine the best path forward for tackling the multifaceted problems caused by meteoroids and orbital debris that put human and robotic space operations at risk."

来源：资阳报